Danish pharma giant Novo Nordisk has made an unsolicited bid of up to US$ 9 billion for U.S. biotech firm Metsera, aiming to outflank rival Pfizer in the rapidly expanding obesity-treatment market. The proposal comprises an upfront cash offer of US$ 56.50 per share plus contingent value rights of up to US$ 21.25 per share.
Metsera, based in New York, specialises in developing next-generation obesity therapies, including its GLP-1 injectable MET-097i and amylin‐analog MET-233i which are at early clinical stages. Pfizer had already agreed in September to acquire Metsera for up to US$ 7.3 billion, including milestone payments. Now, Novo Nordisk’s higher offer challenges that deal.
Novo Nordisk says it sees the acquisition as an opportunity to “maximize the potential” of Metsera’s complementary portfolio and accelerate its position in the obesity space, a segment where it has faced mounting competition from Eli Lilly and Company and others. The obesity-drug market is projected by analysts to reach some US$ 150 billion by the early 2030s as demand surges for weight-loss treatments.
The deal highlights the high stakes in the “anti-obesity arms race.” Novo’s willingness to significantly outbid Pfizer underlines its urgency: the company recently overhauled its board amid investor concerns it was lagging in the obesity segment. The implications span valuations, milestone-based earn-outs, sector consolidation and the risk vs reward for acquiring early-stage biotechs with no approved product yet.
If Novo’s proposal succeeds, it could reshape the competitive landscape, forcing other players to accelerate pipelines, adjust valuations and perhaps rethink partnerships or M&A strategies. However, as always in biotech financing, the key factor remain around the drugs in development deliver clinical proof, regulatory approval and ultimately large-scale commercialisation to justify the high price tag.
